Premium Nahrungsergänzungsmittel | artgerecht

Microsatellite Instability (MSI) – Definition & Significance

Microsatellite instability (MSI) is a genetic phenomenon in which short, repetitive DNA sequences accumulate errors due to a defective DNA repair system, playing a key role in certain cancers.

Regular tips about health Regular tips about health

Things worth knowing about "Microsatellite instability"

Microsatellite instability (MSI) is a genetic phenomenon in which short, repetitive DNA sequences accumulate errors due to a defective DNA repair system, playing a key role in certain cancers.

What is Microsatellite Instability?

Microsatellite instability (MSI) refers to a condition in which short, repetitive DNA sequences known as microsatellites accumulate copying errors. This occurs when the cell's built-in DNA mismatch repair (MMR) system fails to function properly. Microsatellites are short tandem repeat sequences scattered throughout the human genome, and they are particularly vulnerable to replication errors when the MMR system is impaired.

Causes

The primary cause of MSI is a deficiency in the DNA mismatch repair system, which normally corrects small errors that arise during DNA replication. When key MMR genes – such as MLH1, MSH2, MSH6, or PMS2 – are inactivated by mutation or epigenetic silencing (e.g., promoter methylation), errors in microsatellites accumulate uncorrected.

Hereditary: In Lynch syndrome (also known as hereditary non-polyposis colorectal cancer, HNPCC), germline mutations in MMR genes are inherited and predispose individuals to MSI-associated cancers.
Sporadic (acquired): In most MSI-positive tumors, the instability arises from somatic inactivation of the MMR system, most commonly through methylation of the MLH1 promoter.

Clinical Significance and Associated Conditions

MSI is clinically relevant primarily in oncology. It is most frequently detected in the following cancer types:

Colorectal cancer: Approximately 15% of all colorectal cancers exhibit MSI.
Endometrial cancer (uterine cancer)
Gastric cancer (stomach cancer)
Ovarian cancer
Various other solid tumors

Tumors with MSI typically carry a high number of mutations and are classified as MSI-high (MSI-H). In contrast, tumors without this instability are described as microsatellite stable (MSS).

Diagnosis

MSI is detected through molecular analysis of tumor tissue using the following methods:

PCR-based fragment analysis: Comparison of microsatellite lengths between tumor and normal tissue from the same patient.
Immunohistochemistry (IHC): Detection of absent MMR protein expression in tumor tissue, used as a surrogate marker for MSI.
Next-generation sequencing (NGS): A modern approach enabling simultaneous analysis of multiple microsatellite loci and tumor mutational burden.

Treatment Relevance

The MSI status of a tumor has significant implications for treatment decisions:

Immunotherapy: MSI-H tumors respond particularly well to immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab), as their high mutational burden creates more targets for the immune system. The FDA has granted tumor-agnostic approval for pembrolizumab in all solid MSI-H/dMMR tumors.
Prognosis: In early-stage colorectal cancer, MSI-H is generally associated with a more favorable prognosis. In metastatic disease, outcomes may vary.
Chemotherapy response: MSI-H tumors may respond less favorably to certain chemotherapy agents, such as 5-fluorouracil.
Genetic counseling: A positive MSI finding may indicate Lynch syndrome and should prompt further genetic testing and family counseling.

References

Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073-2087. doi:10.1053/j.gastro.2009.12.064
Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine. 2015;372(26):2509-2520.
National Cancer Institute. Mismatch Repair Deficiency and Microsatellite Instability. Available at: https://www.cancer.gov

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.